Alpha 2 Plasmin Inhibitor, Plasma
Plasmin is a key enzyme involved in fibrinolysis in which insoluble fibrin clot is cleaved into soluble fibrin degradation products (FDPs). Physiologically, fibrinolysis by plasmin is inhibited by alpha-2-antiplasmin. Alpha-2-antiplasmin belongs to the serine protease inhibitor family and is synthesized in the liver. It circulates either in the free form or bound to fibrin through the action of factor XIIIa. It has a half-life of approximately 3 days. Once alpha-2-antiplasmin binds to plasmin, it rapidly hydrolyzes and inactivates it. Therefore, alpha-2-antiplasmin plays a key role in the regulation of fibrinolysis.
Decreased levels of alpha-2-antiplasmin are associated with uncontrolled plasmin-mediated fibrinolysis and increase risk of bleeding. Deficiency may cause easy bruising, epistaxis, hematuria, and prolonged bleeding time after trauma or surgery. Congenital deficiency of alpha-2-antiplasmin is rare. Heterozygous individuals may have decreased levels of alpha-2-antiplasmin but typically are clinically asymptomatic. Homozygous individuals have a bleeding disorder characterized by delayed bleeding after injury. Acquired deficiency can be seen in liver diseases, nephrotic syndrome, systemic thrombolytic therapy, disseminated intravascular coagulation (DIC) and acute promyelocytic leukemia. The clinical significance of increased level of alpha 2 antiplasmin is unknown but is believed to be associated with increased risk of ischemic stroke.
- Aid in diagnosis of alpha-2-antiplasmin deficiency – congenital (rare) or acquired
- Laboratory assessment of intravascular coagulation and fibrinolysis and other bleeding disorders
Increased in:
- False-increased results can be seen in patients with elevated alpha-2-macroglobulin
Decreased in:
- Congenital deficiency of alpha-2-plasmin inhibitor
- Systemic thrombolytic therapy
- Acute promyelocytic leukemia
- Nephrotic syndrome
- Disseminated intravascular coagulation (DIC)
Adult: 80 – 140%
Newborn have mildly decreased level (approx. of 50%) which increases to adult level by 90 days of birth.
Platelet-poor Plasma (Sodium citrate or blue top tube).
- Centrifuge to remove plasma and centrifuge the plasma again to get platelet-poor plasma.
- Freeze the plasma below -40 C if not analyzed immediately.
- Avoid anticoagulant medication – Heparin and warfarin before sample collection
Stability
- Ambient: 4 hours
- Refrigerated: 24 hours
- Frozen: 14 days
- Transfus Apher Sci. 2019;58(5):572-577. [PMID: 31427261]
- Int J Lab Hematol. 2018;40 Suppl 1:6-14. [PMID: 29741250]
- Semin Thromb Hemost. 2017;43(2):191-199. [PMID: 27472428]
- Haemophilia. 2008;14(6):1250-4. [PMID: 19141165]